The company said, “We are pleased to share that GraftAssureDx has become, to our knowledge, the first ever kitted dd-cfDNA assay to be submitted to the FDA for regulatory review. Our FDA submission this week represents the culmination of 12 years of clinical development and three years of highly focused technical product development. We see many positive signals that the transplant community is ready for GraftAssureDx.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMDX:
- Insight Molecular Diagnostics reports Q4 EPS (27c) vs. (28c) last year
- OCX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Insight Molecular Diagnostics highlights publication of study on GraftAssure
- Insight Molecular Diagnostics completes milestones advancing GraftAssureDx
- Insight Molecular Diagnostics: GraftAssureIQ Validation and Hospital Adoption Set Up 2026 as a Growth Inflection Year